The "Tumour Targeting, Imaging, Radiotherapies" workshop will focus on therapeutic applications using lutetium-177, demonstrating the evolution of nuclear medicine, an initially diagnostic discipline that is now opening up to the prospect of therapeutic applications. Aspects of production, radiochemistry, dosimetry and imaging, such as pre-therapeutic SPECT imaging protocols, through to clinical trials will be discussed in the case of lutetium-177, but also for alpha and beta emitters as alternatives. The workshop will also address the role of nanovectors for imaging and internal & external radiotherapies. Finally, the latest advances in tumor and microenvironment targeting will be highlighted.